Research area
Lymphoma biologic therapy trials
Every lymphoma study listed here tests a biologic, such as a vaccine, an antibody, or a cell or gene therapy. Whether you are looking for yourself or for someone you care for, Cancer Biologic Trials can help you find out if a study may be a fit.
Updated
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Lymphoma biologic therapy studies in numbers
- lymphoma biologic therapy studies recruiting in the U.S.
- 204
- states with a study site
- 50
- studies that accept healthy volunteers
- 4
Source: ClinicalTrials.gov. Data processed .
Find lymphoma biologic therapy studies by state
These states have the most studies recruiting right now.
California
82 studies recruiting.
Texas
49 studies recruiting.
New York
45 studies recruiting.
Ohio
42 studies recruiting.
Florida
41 studies recruiting.
Washington
40 studies recruiting.
Lymphoma biologic therapy studies recruiting now
As of November 18, 2026, 204 lymphoma biologic therapy studies are recruiting participants in the United States, according to ClinicalTrials.gov. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry. This is what they have in common.
What they test
- biologics such as vaccines or antibodies197
- medications130
- procedures91
- other approaches40
- radiation17
A study can test more than one.
Main purpose
- treating a condition193
- prevention3
- basic science1
- other purposes1
Phase
- Early Phase 13
- Phase 162
- Phase 1/227
- Phase 290
- Phase 2/33
- Phase 313
- Phase 41
- Observational5
Who runs them
- university, hospital or other139
- industry41
- government24
Who they enroll
- adults (18 to 64)201
- older adults (65 and over)179
- mainly children and teens (under 18)13
4 also accept healthy volunteers.
These counts come from each study's public record and change as studies open and close. Browse every location to see what is recruiting near you.
Source: ClinicalTrials.gov. Data processed . Each bar shows a count as a share of all 204 studies.
Recently updated lymphoma biologic therapy studies
The 6 studies whose public records changed most recently, with some of the places each is recruiting. Select a study to read its full record on ClinicalTrials.gov.
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Ankeny, IA · Ann Arbor, MI · Atlanta, GA · and 66 more U.S. locations
- Registry record
- NCT03739814 · updated
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Chicago, IL · Duarte, CA · Mineola, NY · and 5 more U.S. locations
- Registry record
- NCT05272384 · updated
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Akron, OH · Albany, NY · Allentown, PA · and 100 more U.S. locations
- Registry record
- NCT06317662 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Ames, IA · Anaconda, MT · Ankeny, IA · and 210 more U.S. locations
- Registry record
- NCT06337318 · updated
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- University of Washington
- Recruiting in
- Seattle, WA
- Registry record
- NCT06784726 · updated
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 1
- Ages 18 to 120
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Bethesda, MD
- Registry record
- NCT07572136 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in the United States on ClinicalTrials.gov.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and some of the places it is recruiting) exactly as registered. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
What lymphoma biologic therapy studies look at
A vaccine, an antibody, a cell or gene therapy: every lymphoma study listed on this site tests a biologic of that kind. No two of them ask the same things of you. A study is designed around a single question, and the visits and tasks it involves follow from that question, so they differ between studies.
The biologic in any of these studies is investigational. Its risks, and how well it works, are not yet fully understood. Researchers run the study to learn exactly those things, whether you are reading this for yourself or for someone you care for.
Who may be able to take part
Age is one requirement a lymphoma biologic study may set. Your past health, any medicines you currently take, and the way lymphoma affects you can also count. Each study writes its own list. Some are open as well to people without the condition.
Nobody expects you, or a relative reading on your behalf, to figure out whether you fit. That check belongs to the study team, and it takes place during a screening visit. Our guide to eligibility and screening explains the process.
What taking part usually involves
A first conversation
First comes a conversation. A coordinator walks you through the lymphoma biologic study in broad terms and takes your questions, or your family's, before any other step begins.
Informed consent
Next, everything is put on paper for you. The full details of the biologic study, with the risks known so far, come from the study team in writing. Whether to say yes stays your choice.
Screening
Screening for a lymphoma biologic trial means answering health questions and having tests. The results show whether that study suits you, and some people who are screened do not go on to join.
Study visits
Should you decide to take part, your appointments are planned in advance, and each one lets the study team monitor your health along the way. Stopping is your call. You may withdraw from the study whenever you choose.
Questions about lymphoma biologic therapy studies
Do I need a diagnosis to join a study about lymphoma?
That varies from one lymphoma biologic trial to the next. Some want a diagnosis that has been confirmed. In others, assessing you is part of screening itself. You will hear from the study team which one applies.
Would I have to change the care I receive now?
Please leave your current care as it is; nothing should change on your own initiative. Whether it can continue depends on the study: some lymphoma biologic trials permit it, and some don't. That question gets reviewed with you by the study's doctor. Your regular doctor can weigh in too, and there is room for that conversation ahead of any decision.
Is there a cost to take part?
In general, participants do not pay for the medication a study provides, nor for its tests and visits. Our page on costs has more detail.
Ask about lymphoma biologic therapy studies
Send us a few details about you, or about the family member you're asking for, and a coordinator will get in touch. Asking is just asking. You aren't committing to anything.
Independent information
- Lymphoma — National Cancer Institute (NIH)
- What Are Clinical Trials? — National Cancer Institute (NIH)
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)